Recursion Pharmaceuticals (RXRX) Other financing activities (2020 - 2025)

Recursion Pharmaceuticals' Other financing activities history runs 6 years deep, the most recent figure standing at $793000.0 for Q4 2025.

• Quarterly Other financing activities fell 53.63% year-over-year to $793000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 49.74% YoY) and the FY2025 annual result came in at $4.1 million, down 49.74% from the prior year.
• Other financing activities was $793000.0 for Q4 2025 at Recursion Pharmaceuticals, up from -$993000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $460.7 million in Q2 2021 and bottomed at -$458.3 million in Q3 2021.
• A 5-year average of $2.2 million and a median of $2.3 million in 2021 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 2879768.75% in 2021, while the deepest fall reached 201985.9% in 2021.
• Recursion Pharmaceuticals' Other financing activities stood at $3.8 million in 2021, then fell by 6.52% to $3.6 million in 2022, then retreated by 8.63% to $3.3 million in 2023, then plunged by 47.55% to $1.7 million in 2024, then slumped by 53.63% to $793000.0 in 2025.
• Business Quant data shows RXRX's Other financing activities at $793000.0 in Q4 2025, -$993000.0 in Q3 2025, and $2.7 million in Q2 2025.